Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Reconsidering India as a Clinical Trial Location

For many years, India's regulatory environment, coupled with concerns about start-up timelines, data quality and ethics, has made the country a less-than-attractive option for clinical trial sponsors. However, since 2014, authorities have been hard at work revising policies in the favor of clinical research. India's evolving clinical study environment is explored in a new whitepaper.

Click the image to download the full whitepaper